Category - Feature

Feature

Can-Fite preparing protocol for advanced psoriasis trial

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) is preparing the protocol for its next advanced psoriasis trial with its CF101 oral drug candidate, even though an earlier Phase 2/3 study did not meet its primary endpoint...

September 8, 2015

Feature

Hydra Biosciences to have Phase 1 TRPA1 data soon

By Len Zehr Closely-held Hydra Biosciences expects to complete Phase 1 trials of its HX-100 inhibitor of the Transient Receptor Potential (TRPA1) ion channel as a treatment for painful diabetic neuropathy and allergic...

September 1, 2015

Feature

Peritech readies U.S. launch of novel hemorrhoid gel

By Len Zehr Closely-held Peritech Pharma of Israel is in discussions with potential marketing partners for a U.S. launch of its once-daily over-the-counter gel, now known as PP-110, for the treatment of hemorrhoids. “PP...

August 24, 2015

Feature

Cellectar Biosciences refocusing on therapeutics

After completing a strategic review of its cancer therapeutic and cancer diagnostic assets, Cellectar Biosciences (NASDAQ:CLRB) has refocused the company on its phospholipid ether drug conjugate (PDC) platform and...

August 18, 2015

Feature

In conversation with Nicole Grannell

By Len Zehr As vice-president of business development for Bay Area Research Logistics (BARL), a specialized clinical trial design, packaging and logistics firm, Nicole Grannell manages the logistical components of...

August 4, 2015

Feature

Matinas BioPharma moves focus to anti-infectives

By Len Zehr After moving a novel omega-3 program through a successful Phase 2 program, Matinas BioPharma Holdings (OTCQB:MTNB) is now advancing two anti-infective drug candidates in the war against drug resistance. “Our...

July 28, 2015

Feature

Xenon still committed to TV-45070 for neuropathic pain

By Len Zehr Xenon Pharmaceuticals (NASDAQ:XENE) and its development and commercialization partner, Teva Pharmaceutical Industries (NYSE, TASE:TEVA), remain fully committed to the development of TV-45070 for neuropathic...

July 21, 2015

Feature

In conversation with Heather Morehouse Ettinger

By Len Zehr As a partner in the law firm of Troutman Sanders LLP, Heather Morehouse Ettinger focuses her practice on intellectual property due diligence and transaction drafting, intellectual property litigation, and...

July 14, 2015

Feature

M Pharma advancing technologies for obesity and diabetes

By Len Zehr M Pharmaceutical (OTCQB:MPHMF; CSE:MQ; FWB:T3F1.F) is advancing a family of biomedical technologies to manage obesity – TriMeo and TriMtec – and eMosquito to manage diabetes. “All three of our technologies...

July 7, 2015

Feature

Regenicin readying clinical trials of NovaDerm skin substitute

By Len Zehr Regenicin (OTC:RGIN) is completing validation of its NovaDerm skin substitute at a leading institute of technology in the U.S and plans to seek FDA approval to move into clinical trials in the second half of...

June 30, 2015

Category - Feature

General

More